Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Incidence and risk factors for neoplasia in inflammatory bowel disease

Incidence and risk factors for neoplasia in inflammatory bowel disease INTRODUCTIONInflammatory bowel diseases (IBD) are increasingly recognised worldwide. Besides their direct impact on patients and healthcare, they carry additional risks, through both disease and therapy complications. One of the major concerns regarding IBD's natural course and medication impact is the potentially increased risk of developing cancer. On the one hand, most evidence suggests that IBD patients do not harbour an overall higher risk of cancer.1–6 On the other hand, certain cancer subtypes may be more frequent in this population. Indeed, some studies point towards an increased risk of colorectal cancer in IBD,4,7 while others indicate otherwise or suggest that the increased risk is confined to specific subsets of patients.5,6,8–10 Other organs reportedly more affected in IBD are the skin, specifically regarding non‐melanoma skin cancer (NMSC),8,9 which may be the most common cancer in these patients5; the pancreas11 and maybe the breast.6,8 Also, in Crohn's disease (CD), haematological neoplasms,8 renal cell carcinoma,9 cervical9,12 and trachea/lung cancer6 and, in Ulcerative Colitis (UC), prostate9 and thyroid13 cancer may be more common.Another concern is the increased risk of cancer attributed to IBD medication, such as NMSC,8,14–16 urological and haematological neoplasms8,17 associated to thiopurines and the debatable increase in melanoma and lymphoma risks with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Asia-Pacific Journal of Clinical Oncology Wiley

Incidence and risk factors for neoplasia in inflammatory bowel disease

Download PDF
6 pages

Loading next page...
 
/lp/wiley/incidence-and-risk-factors-for-neoplasia-in-inflammatory-bowel-disease-05KyIpNely
Publisher
Wiley
Copyright
© 2023 John Wiley & Sons Australia, Ltd.
ISSN
1743-7555
eISSN
1743-7563
DOI
10.1111/ajco.13908
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONInflammatory bowel diseases (IBD) are increasingly recognised worldwide. Besides their direct impact on patients and healthcare, they carry additional risks, through both disease and therapy complications. One of the major concerns regarding IBD's natural course and medication impact is the potentially increased risk of developing cancer. On the one hand, most evidence suggests that IBD patients do not harbour an overall higher risk of cancer.1–6 On the other hand, certain cancer subtypes may be more frequent in this population. Indeed, some studies point towards an increased risk of colorectal cancer in IBD,4,7 while others indicate otherwise or suggest that the increased risk is confined to specific subsets of patients.5,6,8–10 Other organs reportedly more affected in IBD are the skin, specifically regarding non‐melanoma skin cancer (NMSC),8,9 which may be the most common cancer in these patients5; the pancreas11 and maybe the breast.6,8 Also, in Crohn's disease (CD), haematological neoplasms,8 renal cell carcinoma,9 cervical9,12 and trachea/lung cancer6 and, in Ulcerative Colitis (UC), prostate9 and thyroid13 cancer may be more common.Another concern is the increased risk of cancer attributed to IBD medication, such as NMSC,8,14–16 urological and haematological neoplasms8,17 associated to thiopurines and the debatable increase in melanoma and lymphoma risks with

Journal

Asia-Pacific Journal of Clinical Oncology – Wiley

Published: Mar 13, 2023

Keywords: cancer; crohn's disease; inflammatory bowel disease; neoplasia; ulcerative colitis

References

  • Safety of Biologic Therapy in Older Patients with Immune‐ Mediated Diseases: A Systematic Review and Meta‐Analysis
    Borren, NZ; Ananthakrishnan, AN
  • Systematic review with meta‐analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease
    Piovani, D; Danese, S; Peyrin‐Biroulet, L; Nikolopoulos, GK; Bonovas, S
  • A population‐based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease
    Wilson, JC; Furlano, RI; Jick, SS; Meier, CR
  • Anti‐tumour necrosis factor‐α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population‐based cohort study
    Waljee, AK; Higgins, PDR; Jensen, CB
  • Risk of intestinal and extra‐intestinal cancers in patients with inflammatory bowel diseases: A population‐based cohort study in northeastern Italy
    Taborelli, M; Sozzi, M; Del Zotto, S
  • Marte Lie Høivik, Magne Henriksen ICS. Malignancies in patients with inflammatory bowel disease: Results from 20 years of follow‐up in the IBSEN study
    Hovde, Øistein
  • Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta‐analysis of population‐based cohort studies
    Lutgens, MWMD; Oijen, MGH; Heijden, GJMG; Vleggaar, FP; Siersema, PD; Oldenburg, B
  • Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population‐based IBDSL cohort
    den Heuvel, TRA; Wintjens, DSJ; Jeuring, SFG
  • Cancer Risk in 2621 Chinese Patients with Inflammatory Bowel Disease: A Population‐based Cohort Study
    So, J; Tang, W; Leung, WK
  • Colorectal cancer in ulcerative colitis: a Scandinavian population‐based cohort study
    Olén, O; Erichsen, R; Sachs, MC
  • Inflammatory bowel disease and pancreatic cancer: a Scandinavian register‐based cohort study 1969–2017
    Everhov, ÅH; Erichsen, R; Sachs, MC
  • Inflammatory bowel disease and risk of cervical cancer: A meta‐analysis
    Wang, P; Yan, H; Wang, Z; Dai, L; Xu, S; Wang, B
  • Assessment of thyroid cancer risk in more than 334,000 patients with inflammatory bowel disease: a case‐control study and a meta‐analysis
    Cao, L
  • Repeated Occurrences of Basal Cell Cancer in Patients With Inflammatory Bowel Disease Treated With Immunosuppressive Medications
    Khan, N; Patel, D; Trivedi, C
  • Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: A meta‐analysis
    Ariyaratnam, J; Subramanian, V
  • Risk of skin cancers in thiopurines‐treated and thiopurines‐untreated patients with inflammatory bowel disease: A systematic review and meta‐analysis
    Huang, SZ; Liu, ZC; Liao, WX
  • Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6‐mercaptopurine: A meta‐analysis
    Kotlyar, DS; Lewis, JD; Beaugerie, L
  • Surgical Management of Dysplasia and Cancer in Inflammatory Bowel Disease
    Ansell, J; Grass, F; Merchea, A
  • Managing Patients with Inflammatory Bowel Disease Who Develop Prostate Cancer
    Kim, J; Feagins, LA
  • Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease
    Long, MD; Martin, CF; Pipkin, CA; Herfarth, HH; Sandler, RS; Kappelman, MD
  • Safety of Immune Checkpoint Inhibitors in Patients With Pre‐Existing Inflammatory Bowel Disease and Microscopic Colitis
    Grover, S; Ruan, AB; Srivoleti, P
  • Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta‐analysis
    Singh, S; Nagpal, SJ; Murad, MH; Yadav, S; Kane, S V; Pardi, DS
  • Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
    Beaugerie, L; Brousse, N; Bouvier, AM; Colombel, JF; Lemann, M; Cosnes, J
  • Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6‐mercaptopurine: a meta‐analysis
    Kotlyar, DS; Lewis, JD; Beaugerie, L
  • Risk of lymphoma in patients with inflammatory bowel disease treated with anti‐tumour necrosis factor alpha agents: A systematic review and meta‐analysis
    Yang, C; Huang, J; Huang, X
  • Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
    Bourrier, A; Carrat, F; Colombel, JF
  • Use of azathioprine and the risk of cancer in inflammatory bowel disease
    Pasternak, B; Svanström, H; Schmiegelow, K; Jess, T; Hviid, A
  • Melanoma associated with tumour necrosis factor‐alpha inhibitors: a research on adverse drug events and reports (RADAR) project
    Nardone, B; Hammel, JA; Raisch, DW; Weaver, LL; Schneider, D; West, DP
  • Rheumatoid arthritis, anti‐tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden
    Raaschou, P; Simard, JF; Holmqvist, M; Askling, J; Group, AS
  • Association between tumor necrosis factor‐α antagonists and risk of cancer in patients with inflammatory bowel disease
    Andersen, NN; Pasternak, B; Basit, S
  • T‐cell non‐Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor‐alpha (TNF‐alpha) inhibitors: results of the REFURBISH study
    Deepak, P; Sifuentes, H; Sherid, M; Stobaugh, D; Sadozai, Y; Ehrenpreis, ED
  • Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune‐mediated inflammatory disorders?
    Chen, Y; Friedman, M; Liu, G; Deodhar, A
  • Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta‐Analysis of Placebo‐Controlled Trials
    Peyrin‐Biroulet, L; Deltenre, P; Suray, N; Branche, J; Sandborn, WJ
  • Anti‐TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta‐analysis of rare harmful effects in randomized controlled trials
    Bongartz, T; Sutton, AJ; Sweeting, MJ; Buchan, I; Matteson, EL
  • Colorectal cancer chemoprevention by mesalazine and its derivatives
    Stolfi, C; Pallone, F; Monteleone, G
  • Interaction of salicylates and the other nonsteroidal anti‐inflammatory agents with breast cancer endocrine treatment
    Yiannakopoulou, EC
  • Sulindac inhibits tumor cell invasion by suppressing NF‐kB‐mediated transcription of microRNAs
    Li, X; Gao, L; Cui, Q; Gary, BD; Dyess, DL; Taylor, W
  • Mechanisms of action of non‐steroidal anti‐inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer
    Stolfi, C; De Simone, V; Pallone, F; Monteleone, G
  • Tobacco smoking and cancer: a brief review of recent epidemiological evidence
    Sasco, AJ; Secretan, MB; Straif, K
  • Short‐term toxicity of high dose rate brachytherapy in prostate cancer patients with inflammatory bowel disease
    Mohammed, W; Hoskin, P; Henry, A; Gomez‐Iturriaga, A; Robinson, A; Nikapota, A
  • Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: patient selection and dosimetric parameters with modern treatment techniques
    Murphy, CT; Heller, S; Ruth, K
  • Rates of adverse IBD‐related outcomes for patients with IBD and concomitant prostate cancer treated with radiation therapy
    Feagins, LA; Kim, J; Chandrakumaran, A; Gandle, C; Naik, KH
  • Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
    Abu‐Sbeih, H; Faleck, DM; Ricciuti, B
  • Systematic Review and Meta‐analysis
    Meserve, J; Facciorusso, A; Holmer, AK; Annese, V; Sandborn, WJ; Singh, S
  • Anti‐PD‐1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
    Menzies, AM; Johnson, DB; Ramanujam, S
  • Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
    Johnson, DB; Sullivan, RJ; Ott, PA
  • Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008
    Donin, N; Filson, C; Drakaki, A
  • Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer
    Beaugerie, L; Carrat, F; Colombel, J‐F
  • Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti‐Tumor Necrosis Factor Agents
    Axelrad, J; Bernheim, O; Colombel, J‐F
  • The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register‐Rheumatoid Arthritis
    Silva‐Fernández, L; Lunt, M; Kearsley‐Fleet, L
  • Cancer Recurrence Following Immune‐Suppressive Therapies in Patients With Immune‐Mediated Diseases: A Systematic Review and Meta‐analysis
    Shelton, E; Laharie, D; Scott, FI